炎症性肠病血清CUZD1自身抗体的新型免疫检测方法
本研究以重组CUZD1蛋白为固相抗原,开发了检测IgG和IgA型CUZD1自身抗体的两种免疫荧光分析法,并分析了100例克罗恩病、100例溃疡性结肠炎、129例疑似自身免疫病和50例对照的血清。CUZD1自身抗体在IBD患者中检出率为12.5%(25/200),其中克罗恩病为16%、溃疡性结肠炎为9%(CrD vs. UC,p<0.05),疑似自身免疫病患者为3.1%(4/129)(CrD vs. ADs,p<0.05;UC vs. ADs,p=0.08)。抗体阳性与病变部位、发病年龄或疾病表型无关。
要点
- 新型IgG/IgA CUZD1抗体免疫分析在IBD中检出率为12.5%,Crohn病高于溃疡性结肠炎。
- CUZD1抗体阳性与病变部位、发病年龄及疾病表型无关。
- 该免疫分析与标准间接免疫荧光技术一致性良好,可用于多中心研究。
核心结论
- 首次描述了检测IgA和IgG型CUZD1自身抗体的新型酶联免疫吸附试验,其与标准间接免疫荧光技术一致性良好。
研究设计与样本
- 以重组CUZD1蛋白为固相抗原开发两种免疫分析,检测100例克罗恩病、100例溃疡性结肠炎、129例疑似自身免疫病和50例对照的血清。
主要发现
- CUZD1自身抗体在IBD患者中检出率为12.5%(25/200),克罗恩病为16%、溃疡性结肠炎为9%(CrD vs. UC,p<0.05)。
- 疑似自身免疫病患者CUZD1自身抗体阳性率为3.1%(4/129)(CrD vs. ADs,p<0.05;UC vs. ADs,p=0.08)。
- CUZD1自身抗体阳性与疾病部位、发病年龄或疾病表型无关。
关键数值与推荐
- IBD患者CUZD1自身抗体总阳性率为12.5%(25/200)。
- 克罗恩病患者阳性率为16%,溃疡性结肠炎患者为9%(CrD vs. UC,p<0.05)。
- 疑似自身免疫病患者阳性率为3.1%(4/129)(CrD vs. ADs,p<0.05;UC vs. ADs,p=0.08)。
临床怎么用
- 该新型IgA和IgG CUZD1抗体免疫分析可用于多中心研究,以探究CUZD1自身抗体的诊断和临床价值。
局限性
- 原文未明确报告研究的局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pancreatic autoantibodies (PABs) are detected in patients with inflammatory bowel disease (IBD). Their prevalence is higher in Crohn's disease (CrD) than in ulcerative colitis (UC). Glycoprotein 2 (GP2) and, more recently, CUB and zona pellucida-like domain-containing protein 1 (CUZD1) have been identified as target autoantigens of PAB. The clinical utility of CUZD1 autoantibodies has only recently been assessed by indirect immunofluorescence (IIF) assays. In this study, we developed and validated novel immunoassays for the detection of CUZD1 autoantibodies. METHODS: Recombinant CUZD1 protein was utilized as a solid-phase antigen for the development of two immunoassays for the detection of IgG and IgA CUZD1 autoantibodies. Serum samples from 100 patients with CrD, 100 patients with UC, 129 patients assessed for various autoimmune diseases (vADs) and 50 control individuals were analyzed. RESULTS: Two immunofluorometric assays for the detection of IgG and IgA CUZD1-specific antibodies were developed. CUZD1 autoantibodies were detected in 12.5% (25/200) IBD patients, including 16% of patients with CrD and in 9% of patients with UC (CrD vs. UC, p<0.05), compared with 3.1% (4/129) patients suspected of having vADs (CrD vs. ADs, p<0.05; UC vs. ADs, p=0.08). CUZD1 autoantibody positivity was not found to be related to disease location, age of disease onset or disease phenotype. CONCLUSIONS: This is the first study to describe novel IgA and IgG CUZD1 autoantibody enzyme-linked immunosorbent assay. These immunoassays agree well with standard IIF techniques and can be utilized in multicenter studies to investigate the diagnostic and clinical utility of CUZD1 autoantibodies.
引用
- Farkona S, Soosaipillai A, Filippou P, et al. Novel immunoassays for detection of CUZD1 autoantibodies in serum of patients with inflammatory bowel diseases. Clin Chem Lab Med. 2017. PMID: 28343172. doi:10.1515/cclm-2016-1120
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。